Study to Assess dHER2+AS15 Cancer Vaccine Given in Combination With Lapatinib to Patients With Metastatic Breast Cancer
This study has been completed.
Michael Morse, MD
Information provided by (Responsible Party):
Michael Morse, MD, Duke University Medical Center
First received: August 4, 2009
Last updated: November 15, 2012
Last verified: November 2012
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study has been completed.|
|Study Completion Date:||April 2012|
|Primary Completion Date:||July 2011 (Final data collection date for primary outcome measure)|
|Certification or Request for Extension to Delay Results Received:||November 15, 2012|
Hamilton E, Blackwell K, Hobeika AC, Clay TM, Broadwater G, Ren XR, Chen W, Castro H, Lehmann F, Spector N, Wei J, Osada T, Lyerly HK, Morse MA. Phase 1 clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibition [corrected]. J Transl Med. 2012 Feb 10;10:28. doi: 10.1186/1479-5876-10-28. Erratum in: J Transl Med. 2013;11:82. Morse, Michael A [added].